Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

por Komrokji, R. S., List, A. F.
Publicado 2016

Residual cancer burden in locally advanced breast cancer: a superior tool

por Nahleh, Z., Sivasubramaniam, D., Dhaliwal, S., Sundarajan, V., Komrokji, R.
Publicado 2008

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

por Patnaik, M M, Wassie, E A, Padron, E, Onida, F, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Ketterling, R P, Komrokji, R, Tefferi, A, Solary, E
Publicado 2015

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

por Patnaik, M M, Wassie, E A, Padron, E, Onida, F, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Ketterling, R P, Komrokji, R, Tefferi, A, Solary, E
Publicado 2015

P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND J...

por Zhang, Y., Nguyen, L., Lu, C., Wang, E., Lauw, M., Ball, S., Dong, N., Moscinski, L., Chan, O., Yun, S., Sallman, D., Sokol, L., Shah, B., Lancet, J., Komrokji, R., Kuykendall, A., Padron, E., Zhang, L.
Publicado 2022

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO...

por Mascarenhas, J., Harrison, C. N., Kiladjian, J.-J., Komrokji, R. S., Koschmieder, S., Vannucchi, A. M., Berry, T., Redding, D., Sherman, L., Dougherty, S., Peng, L., Sun, L., Huang, F., Wan, Y., Feller, F. M., Rizo, A., Verstovsek, S.
Publicado 2022

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

por Padron, E, Garcia-Manero, G, Patnaik, M M, Itzykson, R, Lasho, T, Nazha, A, Rampal, R K, Sanchez, M E, Jabbour, E, Al Ali, N H, Thompson, Z, Colla, S, Fenaux, P, Kantarjian, H M, Killick, S, Sekeres, M A, List, A F, Onida, F, Komrokji, R S, Tefferi, A, Solary, E
Publicado 2015

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

por Mora, B., Guglielmelli, P., Kuykendall, A., Maffioli, M., Rotunno, G., Komrokji, R. S., Palandri, F., Kiladjian, J.-J., Iurlo, A., Auteri, G., Cattaneo, D., De Stefano, V., Salmoiraghi, S., Devos, T., Cervantes, F., Merli, M., Campagna, A., Benevolo, G., Brociner, M., Albano, F., Gotlib, J., Caramella, M., Ruggeri, M., Ross, D. M., Orsini, F., Pessina, C., Colugnat, I., Pallotti, F., Barbui, T., Bertù, L., Della Porta, M. G., Vannucchi, A. M., Passamonti, F.
Publicado 2022

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

por Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., Sanz, G.
Publicado 2020